The company continues to report zero revenue while maintaining high-fixed costs, with quarterly R&D spending consistently ranging between $23.4 million and $32.9 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 112.87K | 63K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -112.87K | -63K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | -79.16% | - | - |
| Operating Expenses | 172.25M | 179.04M | 178.21M | 136.92M | 110.4M | 83.22M | 51.68M | 18.45M | 10.54M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 58.26M | 60.6M | 59.17M | 49.4M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 110.07M | 118.44M | 119.04M | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 0 | 286.91K | -2.73M | -2.68M |
| Operating Income | -172.25M | -179.04M | -178.21M | -136.92M | -110.4M | -83.22M | -51.79M | -21.18M | -12.5M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -0.47% | -30.15% | -24.02% | -32.66% | -60.68% | -144.55% | -69.39% | - |
| EBITDA | -36.59M | -178.82M | -177.97M | -136.68M | -110.07M | -83.05M | -51.68M | -21.12M | -12.48M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 80.65% | -0.48% | -30.21% | -24.17% | -32.54% | -60.69% | -144.74% | -69.19% | - |
| D&A (Non-Cash Add-back) | 179K | 216K | 233K | 242K | 330K | 175K | 112.87K | 63K | 22K |
| EBIT | -176.78M | -285.82M | -149.05M | -115.48M | -91.1M | -71.54M | -65.05M | -22.33M | -10.54M |
| Net Interest Income | 2.35M | 2.67M | 3.79M | 2.42M | 0 | 0 | - | 0 | 0 |
| Interest Income | 7.2M | 7.18M | 8.27M | 4.62M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.85M | 4.52M | 4.48M | 2.2M | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -12.01M | -111.3M | 24.68M | 19.23M | 19.31M | 11.68M | -13.26M | 1.58M | -716K |
| Pretax Income | -184.26M | -290.33M | -153.53M | -117.68M | -91.1M | -71.54M | -65.05M | -19.6M | -13.22M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | -5.31M | -2.47M | 1.59M | 780K | 408K | 199K | -4.25M | 15K | 0 |
| Effective Tax Rate % | 2.88% | 0.85% | -1.04% | -0.66% | -0.45% | -0.28% | 6.53% | -0.08% | 0% |
| Net Income | -178.95M | -287.86M | -155.12M | -118.46M | -91.5M | -71.74M | -60.8M | -19.61M | -13.22M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -29.86% | -85.57% | -30.94% | -29.46% | -27.55% | -17.99% | -210.03% | -48.36% | - |
| Net Income (Continuing) | -178.95M | -287.86M | -155.12M | -118.46M | -91.5M | -71.74M | -60.8M | -19.61M | -13.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.91 | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | -2.35 |
| EPS Growth % | -58.29% | -33.91% | 0.86% | -7.41% | -20.67% | -6.55% | -86.67% | 61.7% | - |
| EPS (Basic) | - | -3.08 | -2.30 | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | -2.35 |
| Diluted Shares Outstanding | 93.64M | 93.5M | 67.48M | 51.03M | 42.44M | 40M | 35.93M | 21.72M | 5.62M |
| Basic Shares Outstanding | 110.06M | 93.5M | 67.48M | 51.03M | 42.44M | 40M | 35.93M | 21.72M | 5.62M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Clinical Trial Regulatory Rejection
As reported in financial statements, COMPASS Pathways maintains a high-fixed cost structure, with R&D expenditures consistently ranging between $23.4 million and $32.9 million per quarter, reflecting the significant capital requirements necessary to advance the COMP360 clinical pipeline toward potential regulatory milestones and eventual commercialization.
The company's cost structure remains dominated by clinical trial site management and specialized personnel, which are essential for its drug-plus-protocol delivery model. Investors should monitor whether these R&D outlays yield meaningful clinical data readouts, as the lack of revenue means these expenses directly deplete the company's cash reserves without any offsetting operational income.
Based on the company's reported figures, operating losses have remained stubbornly elevated, fluctuating between $38.4 million and $49.6 million per quarter, indicating that the firm has yet to achieve the operational scale required to begin amortizing its heavy investment in clinical infrastructure and administrative overhead.
The absence of revenue growth means that any increase in SG&A or R&D spending directly expands the operating deficit. This suggests that the company is currently in a high-risk phase where operational efficiency is secondary to the binary outcome of clinical trial success.
According to recent SEC filings, stock-based compensation remains a consistent feature of the income statement, with quarterly charges averaging approximately $3.8 million, which serves to retain specialized scientific talent while simultaneously increasing the dilution risk for existing shareholders during this pre-revenue development stage.
While necessary for talent retention in a competitive biotech landscape, these non-cash expenses effectively obscure the true cash cost of operations. Analysts should adjust for these figures to better understand the underlying burn rate and the potential for future equity dilution as the company approaches critical data readouts.
Market consensus may be overlooking the structural risks inherent in the delivery model, as the requirement for specialized therapist-led sessions suggests that even upon regulatory approval, the company may face significant hurdles in achieving the rapid, high-margin commercial ramp typically expected by growth-oriented biotech investors.
The reliance on a 'human-in-the-loop' therapy protocol implies that future gross margins may be structurally lower than those of traditional pharmaceutical products. This warrants further investigation into whether the company can successfully navigate the logistical complexities of scaling a service-heavy medical intervention without incurring prohibitive operational costs.
Quick answers to the most common questions about buying CMPS stock.
For fiscal year 2025, COMPASS Pathways plc (CMPS) reported total revenue of $0.0M.
COMPASS Pathways plc (CMPS) reported a net loss of $287.9M for the fiscal year ending 2025.